CN101744835A - Tungstenic compound nutriment for preventing and treating calculus and gout class diseases of urinary system - Google Patents
Tungstenic compound nutriment for preventing and treating calculus and gout class diseases of urinary system Download PDFInfo
- Publication number
- CN101744835A CN101744835A CN200910214448A CN200910214448A CN101744835A CN 101744835 A CN101744835 A CN 101744835A CN 200910214448 A CN200910214448 A CN 200910214448A CN 200910214448 A CN200910214448 A CN 200910214448A CN 101744835 A CN101744835 A CN 101744835A
- Authority
- CN
- China
- Prior art keywords
- tungsten
- tungstenic
- urinary system
- acid
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a tungstenic compound nutriment for preventing and treating the calculus and the gout class diseases of the urinary system, which comprises at least one of tungstenic acid or salt, a tungstenic water soluble compound and tungstenic oxide. Tungsten in the tungstenic water soluble compound is +6 valence, +5 valence or +4 valence. The tungstenic oxide is tungstic oxide (WO3), tungsten pentoxide (W2O5) or tungsten dioxide (WO2). The tungstenic compound nutriment replaces or partially replaces clinically common used allopurinol in the treatment of the vesical calculus and the gout class diseases of the urinary system relevant to uric acid and salts thereof and overcomes the influence of the allopurinol on a human body because of influencing the relevant biochemical metabolism of xanthine oxidase, aldehyde oxidase and sulphite oxidase.
Description
Technical field
The present invention relates to contain the nutriment of tungsten compound, especially relate to the Tungstenic compound nutriment of control urinary system calculus and gout class diseases.
Background technology
At present, relevant with uric acid and its esters urinary system calculus, the crazy class disease of pain are more common.To the crazy class disease of pain, clinical allopurinol commonly used (allopurinol) suppresses xanthine oxidase at present, thereby the synthetic catalyzing enzyme of uric acid---xanthine oxidase in inhibition and the cell suppresses the generation of uric acid.But allopurinol can suppress aldehyde oxidase, the sulfite oxidase close with the xanthine oxidase structure equally, like this, the biochemistry metabolism relevant with xanthine oxidase, aldehyde oxidase, sulfite oxidase all can be affected, thereby brings the corresponding adverse factors of human body.
The tungstenic compounds can be used as the succedaneum of allopurinol.+ 6 valence state tungsten salt are by uricopoiesis carbamide in the oxidation human body, carbamide is very easily water-soluble and excrete, equally also can solve the toxic and side effects of uric acid to human body, guaranteed again simultaneously that xanthine oxidase, aldehyde oxidase, sulfite oxidase normal biochemistry metabolism process in human body is unaffected, tungstates is also soluble in water and excrete rapidly in addition, can not cause human body and excessively accumulate and bring side effect.
Present existing source investigation shows, also finds no the enzyme relevant with tungsten in cell at present.But a large amount of simultaneously tungsten of supplying with help the metabolism of uric acid excessive in the human body when human body is supplied with molybdenum in a large number.Uric acid can further react generation carbamide with tungsten under the help of phosphorus in vivo, and this process reaction formula is as follows:
Uric acid+phosphotungstic acid → carbamide+CO
2↑+tungsten blue
Above-mentioned reaction is that wolframic acid and its esters are in the intravital most important reaction of people.
In view of this, the invention provides a kind of Tungstenic compound nutriment of preventing and treating urinary system calculus and gout class diseases, be used in uric acid and relevant urinary system calculus, the crazy class treatment of diseases of pain of its esters, substitute or part substitutes clinical allopurinol commonly used (allopurinol), bring influence because of influencing xanthine oxidase, aldehyde oxidase, the relevant biochemistry metabolism of sulfite oxidase human body to overcome it.
Summary of the invention
The object of the present invention is to provide a kind of Tungstenic compound nutriment of preventing and treating urinary system calculus and gout class diseases, overcoming clinical allopurinol commonly used (allopurinol) because of influencing xanthine oxidase, aldehyde oxidase, the relevant biochemistry metabolism of sulfite oxidase, and bring the corresponding adverse factors of human body.
To achieve these goals, solution of the present invention is as follows:
The Tungstenic compound nutriment of control urinary system calculus and gout class diseases, comprise the acid of tungstenic or salt, and the water soluble compound of tungsten at least a.
In the water soluble compound of described tungsten tungsten be+6 valencys ,+5 valencys ,+4 valencys.
The acid of described tungstenic is hydration phosphotungstic acid H
3PO
40W
12XH
2The water soluble salt of O (x=9～17) and ammonium thereof, sodium, potassium.
The tungstates of described+6 valency tungstenics is the water soluble salt of its ammonium, sodium, potassium, and the paratungstate of+5 valency tungstenics is the water soluble salt of its ammonium, sodium, potassium.
The oxide of described tungsten is Tungstic anhydride. WO
3, tungsten pentoxide W
2O
5, tungsten dioxide mixes the back and forms corresponding water soluble salt adding sodium carbonate, potassium carbonate, sodium hydroxide or potassium hydroxide.
Two tungstates water-soluble condensates, the two wolframic acid diammonium of described+6 valency tungstenics, two wolframic acid disodiums, two wolframic acid dipotassiums.
This Tungstenic compound nutriment is as follows in the action principle of control urinary system calculus and gout class diseases:
Tungsten is can not be by metabolic as a kind of element in vivo, but tungsten is in vivo mainly with W
6+/ W
5+The oxidation valence state can take place mutually to transform, and the interaction of uric acid and its esters oxidoreduction product is influenced the effect of cell interior by their mutual conversion.
W elements highest price attitude is+6 valencys, and electron outside nucleus is d at this moment
0Structure is arranged, and is its most stable valence state, other also have common oxidation state+6 ,+5 ,+4, other low-oxidation-state+1,0 ,-2 can't produce this paper and no longer discusses under physiological condition.The potential energy diagram of W elements element is as follows: (seeing that " inorganic chemistry " (descending) Shao Xuejun, Dong Pingan, Wei Yihai write publishing house of Wuhan University)
Under the acid standard conditions
WO
3——→W
2O
3 
W
2O
3——→WO
2 
WO
2——→W
3+ 
W
3+——→W
Under the alkalescence standard conditions
WO
4 2-——→W
The tungsten WO of+6 valencys
3Oxidation generates the tungsten W of+5 valencys
2O
5Potential change is very big in different H+ solions, and its chemical reaction is as follows:
2WO
3+2H
++e-→W
2O
5+H
2O
The general temperature T of biochemical reaction under the physiological condition, pressure P are constant, and at T=298K, the electromotive force E of above-mentioned reaction has according to energy this spy (Nernst) equation:
E＝E
0-(0.0592/n)1g{(a
5+)/(a
6+)
2×a
H 2}
In the following formula
Be standard electrode potential, n=1 is an electron transfer number, a
H, a
6+, a
6+Be respectively H
+, WO
3, W
2O
5Activity in aqueous solution is supposed above-mentioned reaction except that the H+ ion concentration changes, WO
3, W
2O
5Be still standard state, activity a when H+ concentration is very little
H≈ [H
+], a
6+=1, a
5+=1 has:
E＝E
0+2×0.0592×1g[H
+]
Interior PH=7.4, the WO of valency at this moment+6 of cell under the physiological condition
3Oxidation generates the W of+5 valencys
2O
5Electromotive force:
E
W+6＝-0.906V
In cell mitochondrial, intermembrane space (kytoplasm side or C side) is than endometrial stromal side (M side) [H
+] pH of concentration is approximately big by 1, promptly PH ≈ 6.4, at this moment+6 the tungsten compound WO of valency
3Oxidation generates the W of+5 valencys
2O
5Electromotive force:
E
W+6＝-0.761V
The tungstate ion WO of oxidation state+6
3Oxidation generates the W of+5 valencys
2O
5Electromotive force is all lower basically than the metabolic product of normal cell tricarboxylic acid cycle under the cell physiological condition, the reducing power that is to say it is very strong, oxidability is very faint, in cell basically not with the condition of other reproducibility chemical reaction, opposite endocellular metabolism product have with its at a low price oxidation state be oxidized to the ability of high price oxidation state.It can oxidation uricopoiesis carbamide and carbon dioxide under the help of endocellular phosphorus acid ion, and self quilt is reduced into+the blue mixture of tungsten of 6 valencys and+5 valencys, chemical reaction is as follows:
Uric acid+phosphotungstic acid → carbamide+CO
2↑+tungsten blue
Above-mentionedly be reflected at easier carrying out under the alkali condition, at intracellular PH=7.4, when cell contains phosphoric acid salt and+6 valency tungstates simultaneously in cell directly by carrying out above-mentioned reaction.Following formula reaction mainly be utilize uric acid and+redox reaction between 6 valency tungstates, in analytical chemistry, can carry out the content that colorimetry is measured uric acid by generating tungsten blue, phosphate radical does not participate in oxidoreduction in this reaction changes, phosphate radical mainly works to shelter interfering ion in this reaction, do not have the phosphate radical reaction also can carry out.Generate W in the above-mentioned tungsten blue
6+/ W
5+The ratio of oxidation valence state is not quantitative ratio usually, and the carbamide that generates in the reaction is very easily water-soluble and excrete rapidly.
To human body supply with various valence state tungsten compounds (+6 ,+5 ,+4), O in vivo
2Oxidation under finally be stabilized in+influence biological cell on the tungsten compound of 5～+ 6 valencys.Purine compound or its front body structure of human and animal by containing in assimilating food, and in cell, in cell, generate uric acid by a series of chemical metabolization processes, wolframic acid and its esters by oxidation uric acid in cell after the autoxidation attitude be coupled at uric acid metabolism with the change process of+5～+ 6 valencys, this process can letter be shown as follows:
The biochemical standard electrode potential (see " physical chemistry " Gao Yueying, Dai Lerong, Cheng Humin, neat favorable to the people write, BJ University Press P147) of the biochemical substances that often has in some cells under PH=7, room temperature 298K
The biochemical standard electrode potential φ of some biochemical substances under pH=7, room temperature 298K
| System | Half-cell reaction | Standard electrode potential φ/V |
| ??Cu 2+/Cu +Hemocyanin | ??Cu 2++e→Cu + | ??+0.540 |
| ??Cytf 3+/Cytf 2+Cytochrome | ??Fe 3++e→Fe 2+ | ??+0.365 |
| ??Cyta 3+/Cyta 2+Cytochrome | ??Fe 3++e→Fe 2+ | ??+0.290 |
| ??Cytc 3+/Cytc 2+Cytochrome | ??Fe 3++e→Fe 2+ | ??+0.254 |
| ??Fe 3+/Fe 2+Hemoglobin | ??Fe 3++e→Fe 2+ | ??+0.170 |
| ??Fe 3+/Fe 2+Myoglobin | ??Fe 3++e→Fe 2+ | ??+0.046 |
| ??Fe 3+/Fe 2+Ferredoxin | ??Fe 3++e→Fe 2+ | ??+0.031 |
| Fumarate/succinate | ?? -OOCCH＝CHOO -+2H ++2e??→ -OOCCH 2CH 2OO - | ??+0.011 |
| ??MB/MBH 2 | ??MB+2H ++2e→MBH 2 | ??-0.166 |
| System | Half-cell reaction | Standard electrode potential φ/V |
| Oxalic acid acetate/malate | ?? -OOC-COCH 2COO -+2H ++2e→?? -OOCCHOHCH 2COO - | ??-0.185 |
| Pyruvate/lactate | ??CH 3COCOO -+2H ++2e→??CH 3CHOHCOO - | ??-0.197 |
| Acetaldehyde/ethanol | ??CH 3CHO+2H ++2e→CH 3CH 2OH | ??-0.219 |
| ??FAD/FADH 2 | ??FAD+2H ++2e→FADH 2 | ??-0.320 |
| ??NAD +/NADH | ??NAD ++2H ++2e→NADH+H + | ??0.324 |
| ??NADP +/NADPH | ??NADP ++2H ++2e→NADPH+H + | ??-0.420 |
| ??CO 2/ formates | ??CO 2+H ++2e→HCOO - | ??-0.421 |
| ??H +/H 2 | ??2H ++2e→H 2 | ??-0.432 |
| Acetic acid/acetaldehyde | ??CH 3COOH+2H ++2e→??CH 3CHO+H 2O | ??-0.581 |
| Acetate/pyruvate | ??CH 3COOH+CO 2+2H ++2e→??CH 3COCOOH+H 2O | ??-0.700 |
Contrast as can be known under intracellular physiological condition from above standard electrode potential, the oxidability of tungsten compound is very faint, basically do not take place except that with uric acid redox reaction, exactly because so, they are not in vivo usually because excessive intensive oxidation reaction, can not cause the various biochemicals in the humans and animals cell, in the body fluid of extracellular by the redox reaction considerable damage, with respect to chromic acid H
2CrO
4, mangaic acid HMnO
4Deng and the strong oxide of its esters they be foolproof on redox characteristic to humans and animals.
The tungstates of+6 valencys has the special nature of reacting with uric acid at human body, it can suitably supply with the chemical compound of the enough tungstates of human body or other valence state effectively at because of xanthine oxidase over oxidation xanthine causes the crazy disease symptoms of pain to increase the weight of to uric acid in the body and the raising of its esters chemical substance concentration.Just can avoid the uric acid disease that causes because of xanthine oxidase over oxidation xanthine fully.
This Tungstenic compound nutriment has safety on using.Tungsten and insoluble tungsten compound are difficult for absorbing at gastrointestinal tract, and soluble tungsten chemical compound and tungstates can be from gastrointestinal absorption, and the absorbance of tungstates can be up to 40%～80%.But the aerosol of respiratory tract absorption portion tungsten, the respiratory tracts that are deposited on more than half of suction.After tungsten absorbs, discharge rapidly in 24 hours, remaining very fraction (about 2%) mainly is stored in skeleton, is liver, kidney, lung, muscle secondly.The discharge approach of tungsten is mainly discharged through urine and stool, and it is 2～13ug that the normal person urinates the tungsten discharge every day.
Tungsten and chemical compound thereof belong to lower toxicity.The LD of its mouse oral sodium tungstate
50Be 240mg/kg, rat is 1190mg/kg.25～80g of human oral tungsten compound does not see that poisoning symptom is arranged.The workman of melting wolfram steel sucks Tungstic anhydride., intoxicating phenomenons such as malaise, heating, albuminuria, erythra can occur, cures through 1～2 week of anti symptom treatment.
The most obvious, rapid-action with the tungstates effect to the crazy patient of pain in tungsten and the chemical compound thereof, the chemical compound of other valence state need be from other valence state by intracellular oxygen O
2After the oxidation, the scavenging action to uric acid just can take place in the tungstate radicle that generates+6 valencys under the assistance of intracellular phosphate radical.For general crowd, 2～4g/ of human oral tungsten compound every day (50kg body weight) does not see that poisoning symptom is arranged, and simultaneously uric acid is had better scavenging action.
The specific embodiment
The selection of tungsten compound
Under normal temperature condition, the oxide Tungstic anhydride. WO of wolframic acid, tungsten
3, tungsten pentoxide W
2O
5Or tungsten dioxide WO
2Water insoluble, but be soluble in the solution of the aqueous solution of alkali metal hydroxide and alkali metal hydroxide and carbonate, the oxide of wolframic acid, tungsten generally is difficult to directly be absorbed by the mankind.Hydration phosphotungstic acid H
3PO
40W
12.xH
2Water soluble salts such as O (x=9～17) and ammonium thereof, sodium, potassium, water soluble salts such as the ammonium in the tungstates, sodium, potassium, water soluble salts such as the ammonium of the paratungstate of+5 valency tungstenics, sodium, potassium, wolframic acid water-soluble condensate two wolframic acid diammonium, two wolframic acid disodiums, two wolframic acid dipotassiums, these chemical compounds water solublity at normal temperatures are bigger, so can directly use, and be absorbed by the mankind easily.
Two or more mixing is used and is had phase effect roughly the same in above-mentioned tungsten compound, and what we were desired is to have the WO that the anion thing is levied in the compound structure
4 2-In histiocyte unique oxidation uric acid of performance and salt thereof chemical action, and the WO that levies of anion thing
4 2-In histiocyte, very easily excrete, so we control WO in the Tungstenic compound nutriment prescription
4 2-Anionic dosage gets final product.
Tungsten and chemical compound thereof belong to lower toxicity.The LD of its mouse oral sodium tungstate
50Be 240mg/kg, rat is 1190mg/kg.25～80g of human oral tungsten compound does not see that poisoning symptom is arranged.They very easily excrete the seldom poisonous secondary chemical action of residue after stopping using.For general crowd, 2～4g/ of human oral sodium tungstate every day (50kg body weight) does not see that poisoning symptom is arranged, simultaneously uric acid there is better scavenging action, is converted into molecular number sodium tungstate 4g/ (50kg body weight every day) and is 0.02mol/ (50kg body weight every day).
When using different water solublity tungstates, control WO
4 2-Anionic accumulated dose is safe to human body in 0.02mol/ (50kg body weight every day); If use when two or more mixes in the above-mentioned water solublity tungsten compound control WO
4 2-Anionic accumulated dose is safe to human body in 0.02mol/ (50kg body weight every day); If use the oxide of tungsten to be dissolved in the solution of the aqueous solution of alkali metal hydroxide and alkali metal hydroxide and carbonate, with the molecular amounts of tungsten oxide by accumulated dose in 0.02mol/ (50kg body weight every day), be safe to human body.
Embodiment
We are to adopt tungstate dihydrate acid sodium Na
2WO
42H
2O is as Tungstenic compound nutriment.At different rheumatic gonarthritis and regular neck acid rise, the urinary system calculus patient, quantitatively take the tungstate dihydrate acid sodium of specified quantitative every day, concrete outcome is as follows:
The result shows, tungstate dihydrate acid sodium nutrition product to gout class diseases, chronic rheumatic gonarthritis and regular neck acid rise, urinary system calculus all has significant remission effect.
The variation that is appreciated that a lot of details is possible, but therefore this do not run counter to scope and spirit of the present invention, and any person of an ordinary skill in the technical field all should be considered as not breaking away from the category of patent of the present invention to its suitable variation of doing.
Claims (6)
1. the Tungstenic compound nutriment of control urinary system calculus and gout class diseases, it is characterized in that comprising the acid of tungstenic or salt, and the water soluble compound of tungsten at least a.
2. prevent and treat the Tungstenic compound nutriment of urinary system calculus and gout class diseases according to claim 1, it is characterized in that: in the water soluble compound of tungsten tungsten for+6 valencys ,+5 valencys ,+4 valencys.
3. prevent and treat the Tungstenic compound nutriment of urinary system calculus and gout class diseases according to claim 1, it is characterized in that: the acid of tungstenic is hydration phosphotungstic acid H
3PO
40W
12XH
2The water soluble salt of O (x=9～17) and ammonium thereof, sodium, potassium.
4. prevent and treat the Tungstenic compound nutriment of urinary system calculus and gout class diseases according to claim 1, it is characterized in that: the tungstates of+6 valency tungstenics is the water soluble salt of its ammonium, sodium, potassium, and the paratungstate of+5 valency tungstenics is the water soluble salt of its ammonium, sodium, potassium.
5. prevent and treat the Tungstenic compound nutriment of urinary system calculus and gout class diseases according to claim 1, it is characterized in that: the oxide of tungsten is Tungstic anhydride. WO
3, tungsten pentoxide W
2O
5, tungsten dioxide mixes the back and forms corresponding water soluble salt adding sodium carbonate, potassium carbonate, sodium hydroxide or potassium hydroxide.
6. prevent and treat the Tungstenic compound nutriment of urinary system calculus and gout class diseases according to claim 1, it is characterized in that: two tungstates water-soluble condensates, the two wolframic acid diammonium of+6 valency tungstenics, two wolframic acid disodiums, two wolframic acid dipotassiums.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910214448A CN101744835A (en) | 2009-12-30 | 2009-12-30 | Tungstenic compound nutriment for preventing and treating calculus and gout class diseases of urinary system |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910214448A CN101744835A (en) | 2009-12-30 | 2009-12-30 | Tungstenic compound nutriment for preventing and treating calculus and gout class diseases of urinary system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101744835A true CN101744835A (en) | 2010-06-23 |
Family
ID=42472851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910214448A Pending CN101744835A (en) | 2009-12-30 | 2009-12-30 | Tungstenic compound nutriment for preventing and treating calculus and gout class diseases of urinary system |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101744835A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2551828A1 (en) * | 2014-05-21 | 2015-11-23 | Oxolife S.L. | Food compositions comprising tungsten salts (VI) (Machine-translation by Google Translate, not legally binding) |
-
2009
- 2009-12-30 CN CN200910214448A patent/CN101744835A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2551828A1 (en) * | 2014-05-21 | 2015-11-23 | Oxolife S.L. | Food compositions comprising tungsten salts (VI) (Machine-translation by Google Translate, not legally binding) |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xie et al. | Effects of vanadium (III, IV, V)-chlorodipicolinate on glycolysis and antioxidant status in the liver of STZ-induced diabetic rats | |
| US4968716A (en) | Compositions and methods for administering therapeutically active compounds | |
| Satter et al. | In vitro lactate metabolism by ruminal ingesta | |
| Perry Jr et al. | Elevated systolic pressure following chronic low-level cadmiun feeding | |
| CN108872217A (en) | The synthesis and application of iridium dioxide nano enzyme | |
| Jelikić-Stankov et al. | Compounds of Mo, V and W in biochemistry and their biomedical activity | |
| CN104620853B (en) | A kind of breeding method of Se-rich lucid ganoderma conidia powder or fructification | |
| CN101744835A (en) | Tungstenic compound nutriment for preventing and treating calculus and gout class diseases of urinary system | |
| CN112522364B (en) | Uric acid kit for rapidly and simply eliminating interference of calcium dobesilate and phenol sulfoethylamine drugs in serum | |
| Gingell et al. | Species differences in the acute toxicity and tissue distribution of DDT in mice and hamsters | |
| Brewer et al. | A comparison of inulin, paraaminohippuric acid, and endogenous creatinine clearances as measures of renal function in neonatal foals | |
| CN102875458B (en) | Synthesis method of chromium 2-pyridylformate | |
| Cope | Nonprotein nitrogen (urea) and hyperammonemia | |
| CN103913440A (en) | Detection method and reagent of enzyme activity of pyruvate dehydrogenase complex | |
| Said et al. | Absorption of 5-methyltetrahydrofolate in rat jejunum with intact blood and lymphatic vessels | |
| EP0417209B1 (en) | Compositions and methods for administering therapeutically active compounds | |
| CN112390857A (en) | Phosphorylated pentapeptide as uranium excretion promoter in uranium poisoning | |
| Dashti et al. | The effect of nitric oxide donor in diabetic wound healing | |
| CN105503588A (en) | Supermolecular gelator compound and synthesis and application thereof to preparation of gel-type sensor array | |
| CN101963611A (en) | Clinical assay reagent, kit and method | |
| Nelson et al. | Metabolic studies of high doses of allopurinol in humans | |
| Kolganova | Reducing methane Emissions from Ruminants | |
| WO2023109826A1 (en) | Use of silver carbonate in preparation of medicament | |
| KOERTS* et al. | Metabolism of the insecticide teflubenzuron in rats | |
| JP2014200778A (en) | Antioxidative drinking water |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20100623 |